Theresa Human1, Aaron M Cook2, Brian Anger3, Kathleen Bledsoe4, Amber Castle5, David Deen6, Haley Gibbs7, Christine Lesch8, Norah Liang9, Karen McAllen10, Christopher Morrison11, Dennis Parker12, A Shaun Rowe13, Denise Rhoney14, Kiranpal Sangha15, Elena Santayana16, Scott Taylor17, Eljim Tesoro18, Gretchen Brophy19. 1. Barnes Jewish Hospital, Washington University St. Louis, St. Louis, MO, USA. 2. University of Kentucky, Lexington, KY, USA. 3. Saint Louis University Hospital, St. Louis, MO, USA. 4. University of Virginia Health System, Charlottesville, VA, USA. 5. Yale-New Haven Hospital, New Haven, CT, USA. 6. Memorial University Center, Savannah, GA, USA. 7. Johns Hopkins Hospital, Baltimore, MD, USA. 8. New York Presbyterian Hospital, New York, NY, USA. 9. Hartford Hospital, Hartford, CT, USA. 10. Spectrum Health, Grand Rapids, MI, USA. 11. Jackson Memorial Hospital, Miami, FL, USA. 12. Detroit Receiving Hospital, Detroit, MI, USA. 13. University of Tennessee, Knoxville, TN, USA. 14. University of North Carolina, Chapel Hill, NC, USA. 15. University of Cincinnati-University Hospital, Cincinnati, OH, USA. 16. University of Chicago Medical Center, Chicago, IL, USA. 17. Via Cristi, Wichita, KS, USA. 18. University of Illinois-Chicago, Chicago, IL, USA. 19. Virginia Commonwealth of Virginia, Medical College of Virginia, Richmond, VA, USA. gbrophy@vcu.edu.
Abstract
BACKGROUND: Little data exist regarding the practice of sodium management in acute neurologically injured patients. This study describes the practice variations, thresholds for treatment, and effectiveness of treatment in this population. METHODS: This retrospective, multicenter, observational study identified 400 ICU patients, from 17 centers, admitted for ≥48 h with subarachnoid hemorrhage (SAH), traumatic brain injury (TBI), intraparenchymal hemorrhage, or intracranial tumors between January 1, 2011 and July 31, 2012. Data collection included demographics, APACHE II, Glascow Coma Score (GCS), serum sodium (Na+), fluid rate and tonicity, use of sodium-altering therapies, intensive care unit (ICU) and hospital length of stay, and modified Rankin score upon discharge. Data were collected for the first 21 days of ICU admission or ICU discharge, whichever came first. Sodium trigger for treatment defined as the Na+ value prior to treatment with response defined as an increase of ≥4 mEq/L at 24 h. RESULTS: Sodium-altering therapy was initiated in 34 % (137/400) of patients with 23 % (32/137) having Na+ >135 mEq/L at time of treatment initiation. The most common indications for treatment were declining serum Na+ (68/116, 59 %) and cerebral edema with mental status changes (21/116, 18 %). Median Na+ treatment trigger was 133 mEq/L (IQR 129-139) with no difference between diagnoses. Incidence and treatment of hyponatremia was more common in SAH and TBI [SAH (49/106, 46 %), TBI (39/97, 40 %), ICH (27/102, 26 %), tumor (22/95, 23 %); p = 0.001]. The most common initial treatment was hypertonic saline (85/137, 62 %), followed by oral sodium chloride tablets (42/137, 31 %) and fluid restriction (15/137, 11 %). Among treated patients, 60 % had a response at 24 h. Treated patients had lower admission GCS (12 vs. 14, p = 0.02) and higher APACHE II scores (12 vs. 10, p = 0.001). There was no statistically significant difference in outcome when comparing treated and untreated patients. CONCLUSION: Sodium-altering therapy is commonly employed among neurologically injured patients. Hypertonic saline infusions were used first line in more than half of treated patients with the majority having a positive response at 24 h. Further studies are needed to evaluate the impact of various treatments on patient outcomes.
BACKGROUND: Little data exist regarding the practice of sodium management in acute neurologically injured patients. This study describes the practice variations, thresholds for treatment, and effectiveness of treatment in this population. METHODS: This retrospective, multicenter, observational study identified 400 ICU patients, from 17 centers, admitted for ≥48 h with subarachnoid hemorrhage (SAH), traumatic brain injury (TBI), intraparenchymal hemorrhage, or intracranial tumors between January 1, 2011 and July 31, 2012. Data collection included demographics, APACHE II, Glascow Coma Score (GCS), serum sodium (Na+), fluid rate and tonicity, use of sodium-altering therapies, intensive care unit (ICU) and hospital length of stay, and modified Rankin score upon discharge. Data were collected for the first 21 days of ICU admission or ICU discharge, whichever came first. Sodium trigger for treatment defined as the Na+ value prior to treatment with response defined as an increase of ≥4 mEq/L at 24 h. RESULTS:Sodium-altering therapy was initiated in 34 % (137/400) of patients with 23 % (32/137) having Na+ >135 mEq/L at time of treatment initiation. The most common indications for treatment were declining serum Na+ (68/116, 59 %) and cerebral edema with mental status changes (21/116, 18 %). Median Na+ treatment trigger was 133 mEq/L (IQR 129-139) with no difference between diagnoses. Incidence and treatment of hyponatremia was more common in SAH and TBI [SAH (49/106, 46 %), TBI (39/97, 40 %), ICH (27/102, 26 %), tumor (22/95, 23 %); p = 0.001]. The most common initial treatment was hypertonicsaline (85/137, 62 %), followed by oral sodium chloride tablets (42/137, 31 %) and fluid restriction (15/137, 11 %). Among treated patients, 60 % had a response at 24 h. Treated patients had lower admission GCS (12 vs. 14, p = 0.02) and higher APACHE II scores (12 vs. 10, p = 0.001). There was no statistically significant difference in outcome when comparing treated and untreated patients. CONCLUSION:Sodium-altering therapy is commonly employed among neurologically injured patients. Hypertonicsaline infusions were used first line in more than half of treated patients with the majority having a positive response at 24 h. Further studies are needed to evaluate the impact of various treatments on patient outcomes.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Adnan I Qureshi; M Fareed K Suri; Gene Y Sung; Robert N Straw; Abutaher M Yahia; Mustafa Saad; Lee R Guterman; L Nelson Hopkins Journal: Neurosurgery Date: 2002-04 Impact factor: 4.654
Authors: Jacek M Kwiecien; Wojciech Dąbrowski; Jordan R Yaron; Liqiang Zhang; Kathleen H Delaney; Alexandra R Lucas Journal: Curr Neuropharmacol Date: 2021 Impact factor: 7.363